Aster DM Healthcare, one of India’s leading integrated healthcare service providers announced a steady financial performance for the third quarter of the 2025–26 fiscal year with revenue growing 13 percent year-on-year to ₹1,186 crore for the quarter ended December 31, 2025. According to the company’s earnings disclosure, operating EBITDA (excluding the newly commissioned Kasaragod facility) climbed 17 percent to ₹237 crore while operating EBITDA margins improved to 20.2 percent in Q3 FY26 from 19.3 percent in the year-ago period. Normalised profit after tax (PAT) grew 22 percent to ₹98 crore, underscoring the company’s focus on cost management and operational efficiency.
In addition to the standalone results, Aster reported strong performance on a combined proforma basis with Quality Care India Limited (QCIL), as the proposed merger moves closer to completion. On this basis, proforma revenue rose 15 percent year-on-year to ₹2,366 crore, while operating EBITDA increased 22 percent to ₹503 crore, with margins holding at 21 percent. A shareholders’ meeting to further the merger process is scheduled between February 27 and March 13, 2026, following a National Company Law Tribunal (NCLT) order.
Commenting on the results, Dr. Azad Moopen, Founder and Chairman of Aster DM Healthcare, said the combined platform’s performance remained “encouraging” across the quarters of FY26, driven by strong patient volumes and an improving case mix. He highlighted that the combined entity has added over 560 beds, taking total capacity to more than 10,620 beds across 28 cities, with a pipeline of over 4,000 additional beds planned to support long-term growth.
Aster’s performance reflects underlying momentum in both its domestic and international operations, supported by expanded clinical services and enhanced capabilities across its network. The company’s progress toward merger completion with QCIL is expected to further strengthen its competitive position in the Indian healthcare market.